Previous 10 | Next 10 |
Applied UV (NASDAQ:AUVI) +47%. Skylight Health Group (NASDAQ:SLHG) +27%. Ardelyx (NASDAQ:ARDX) +18%. IceCure Medical (NASDAQ:ICCM) +17%. Energy Focus (NASDAQ:EFOI) +17%. Ambarella (NASDAQ:AMBA) +15% on Q3 results VBI Vaccines (NASDAQ:VBIV) +14% wins FDA approval for Hepatitis B vacc...
VBI Vaccines (NASDAQ:VBIV) is trading ~9.2% higher on above-average volume in the premarket after the company announced the FDA approval of PreHevbrio [Hepatitis B Vaccine (Recombinant)] to prevent Hep B infection in adults aged 18 years and older. The approval was based on two late...
- PreHevbrio™ is the only approved 3-antigen hepatitis B vaccine for adults in the U.S. - Shareholder conference call to be held today, December 1, at 8:30 AM ET VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursui...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, President and CEO, will participate in an analyst-led fireside chat at the Jefferies London Healthca...
VBI Vaccines (NASDAQ:VBIV): Q3 GAAP EPS of -$0.06 beats by $0.01. Revenue of $0.11M (-63.3% Y/Y) misses by $0.15M. Press Release VBIV ended the third quarter of 2021 with $137.5M in cash, cash equivalents, and short-term investments compared with $93.8M as of December 31, 2020. For further ...
Hepatitis B (HBV) : Prophylactic : FDA and EMA regulatory review of VBI’s 3-antigen prophylactic HBV vaccine candidate ongoing – U.S. PDUFA target action date November 30, 2021 On November 3, the CDC’s ACIP unanimously passed a universal HBV va...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that its abstract highlighting data from PROTECT, the pivotal Phase 3 immunogenicity and safety study of its 3-antigen...
VBI Vaccines will find out on November 30th whether its Hepatitis B vaccine - already approved in Israel - will be approved by the FDA in the US. Approval in the US - and Europe, where a marketing authorization is also being sought - could be a potential game-changer for the company, ...
Publication title: “Immunogenicity and safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine; A Phase 3 Randomized Clinical Trial” The Phase 3 study, in 2,838 adults age 18-45, evaluated immunogenicity, safety, and lot-to-lot manuf...
Applied UV (NASDAQ:AUVI) +41% on KES Science & Technology assets acquisition GeoVax Labs (NASDAQ:GOVX) +24% after deal for clinical-stage cancer program NuCana (NASDAQ:NCNA) +15% receives fast track designation from the U.S. Food and Drug Administration for Acelar...
News, Short Squeeze, Breakout and More Instantly...
Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024 The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, wa...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s ca...
PreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) anno...